HOSPITAL UNIVERSITARIO RUBER
Departamento
Fondazione IRCCS Istituto Nazionale dei Tumori
Milán, ItaliaPublicaciones en colaboración con investigadores/as de Fondazione IRCCS Istituto Nazionale dei Tumori (24)
2024
-
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
The Lancet
-
Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis
ESMO Open, Vol. 9, Núm. 3
-
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial
European Journal of Nuclear Medicine and Molecular Imaging
2023
-
Correction to: Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group (Pediatric Research, (2022), 91, 5, (1069-1077), 10.1038/s41390-021-01587-3)
Pediatric Research
-
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
Annals of Oncology, Vol. 34, Núm. 8, pp. 645-659
-
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
The oncologist, Vol. 28, Núm. 1, pp. 23-32
2022
-
Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group
Pediatric Research, Vol. 91, Núm. 5, pp. 1069-1077
-
Rethinking breast cancer follow-up based on individual risk and recurrence management
Cancer Treatment Reviews, Vol. 109
2021
-
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
The Lancet Oncology, Vol. 22, Núm. 6, pp. 858-871
-
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2 -Negative Advanced Breast Cancer: A Randomized Clinical Trial
JAMA Oncology, Vol. 7, Núm. 12, pp. 1791-1799
-
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
npj Breast Cancer, Vol. 7, Núm. 1
-
Nobody dares stopping clinical research, not even COVID-19
npj Breast Cancer
2020
-
Commentary: SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China
Frontiers in Oncology, Vol. 10
-
Correction: NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer (Breast Cancer Research (2019) 21 (133) DOI: 10.1186/s13058-019-1196-y)
Breast Cancer Research
-
ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer
ESMO Open, Vol. 5
-
Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019
European Journal of Cancer, Vol. 135, pp. 62-65
-
Trastuzumab emtansine plus non-pegylated liposomal doxorubicin in HER2-positive metastatic breast cancer (Thelma): A single-arm, multicenter, phase Ib trial
Cancers, Vol. 12, Núm. 12, pp. 1-14
2019
2016
-
Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts
Oncotarget, Vol. 7, Núm. 42, pp. 67956-67965